Home / Blog / Insulin & Oral Antidiabetic Drugs: Where Each Class Acts
Endocrine System

Insulin & Oral Antidiabetic Drugs: Where Each Class Acts

13 Jun 2026 2 min read By admin

Type 2 diabetes is a disease of too little insulin and too much resistance — so its drugs work at several different organs. Learn the antidiabetics by the organ each one targets, and the mechanisms, benefits and key adverse effects line up neatly.

↓ Glucose control Pancreas — ↑ insulin secretion Sulfonylureas (glimepiride), meglitinides, GLP-1 agonists, DPP-4 inhibitors Liver — ↓ gluconeogenesis Metformin (first-line); reduces hepatic glucose output Muscle & fat — ↑ sensitivity Thiazolidinediones (pioglitazone), metformin Kidney — ↑ glucose excretion SGLT2 inhibitors (empagliflozin, dapagliflozin) Gut — slow carbohydrate uptake α-glucosidase inhibitors (acarbose); GLP-1 agonists slow gastric emptying Incretin axis GLP-1 agonists (-tides), DPP-4 inhibitors (-gliptins): glucose-dependent
Antidiabetic drugs act across six organs — pancreas, liver, muscle/fat, kidney, gut and the incretin axis.

Insulin — the backbone of type 1

  • Rapid-acting (lispro, aspart) — mealtime cover.
  • Short (regular), intermediate (NPH), and long-acting (glargine, detemir) — basal cover.
  • Main risk: hypoglycaemia; also weight gain and injection-site lipodystrophy.

Metformin — first-line in type 2

A biguanide that reduces hepatic gluconeogenesis and improves insulin sensitivity. No hypoglycaemia, no weight gain. Caution: GI upset and rare lactic acidosis (avoid in renal impairment; withhold around contrast).

Insulin secretagogues

  • Sulfonylureas (glimepiride, gliclazide) close the K-ATP channel → insulin release. Cause hypoglycaemia and weight gain.
  • Meglitinides (repaglinide) — shorter, taken with meals.

Insulin sensitisers

Thiazolidinediones (pioglitazone) activate PPAR-γ. Watch for fluid retention, weight gain and fracture risk; avoid in heart failure.

The incretin drugs

  • GLP-1 receptor agonists (semaglutide, liraglutide) — glucose-dependent insulin release, slow gastric emptying, weight loss and proven cardiovascular benefit.
  • DPP-4 inhibitors (sitagliptin) — oral, weight-neutral, well tolerated.

SGLT2 inhibitors

Empagliflozin, dapagliflozin block glucose reabsorption in the proximal tubule → glucose excreted in urine. Major cardiovascular and renal benefits; risks: genital infections, volume depletion, and euglycaemic diabetic ketoacidosis.

α-glucosidase inhibitors

Acarbose slows intestinal carbohydrate digestion — modest effect, flatulence.

Exam tip: sort the drugs by whether they cause hypoglycaemia (insulin, sulfonylureas, meglitinides) or not (metformin, GLP-1, DPP-4, SGLT2, pioglitazone, acarbose). The agents with cardiovascular/renal benefit — GLP-1 agonists and SGLT2 inhibitors — are today’s favourite exam material.

Map each class to its organ, then remember its one defining feature — hypoglycaemia risk, weight effect, or organ benefit — and the whole of diabetes pharmacology becomes a single, logical picture.

Test yourself

0 / 2

A quick check on this topic — tap an answer for instant feedback.

  1. Q1. Which is first-line in type 2 diabetes and does NOT cause hypoglycaemia?

  2. Q2. SGLT2 inhibitors lower glucose by acting on the:

Question 1 of 2
Share
Endocrine System
← All articles